EUVIMEDEUVIMED entdecken
Leitlinie

Fine-Tuning Cancer Risk and Response: Practical Implications of the 2025 ATA Differentiated Thyroid Cancer Guidelines

Maya Taleb, Natalia Genere

Clinical Thyroidology® · 01.11.2026 · 38 (11) · 389-392

DOI: 10.1177/23299711261506067 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Clinical Thyroidology®, online erschienen am 16.11.2026. Verfasst von Maya Taleb und 1 weiteren Autor:innen. Die Arbeit nennt 8 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Taleb, M., & Genere, N. (2026). Fine-Tuning Cancer Risk and Response: Practical Implications of the 2025 ATA Differentiated Thyroid Cancer Guidelines. Clinical Thyroidology®, 38(11), 389-392. https://doi.org/10.1177/23299711261506067

Vancouver

Taleb M, Genere N. Fine-Tuning Cancer Risk and Response: Practical Implications of the 2025 ATA Differentiated Thyroid Cancer Guidelines. Clinical Thyroidology®. 2026;38(11):389-392. doi:10.1177/23299711261506067

BibTeX
@article{Taleb2026,
  author = {Taleb, Maya and Genere, Natalia},
  title = {Fine-Tuning Cancer Risk and Response: Practical Implications of the 2025 ATA Differentiated Thyroid Cancer Guidelines},
  journal = {Clinical Thyroidology®},
  year = {2026},
  volume = {38},
  number = {11},
  pages = {389--392},
  doi = {10.1177/23299711261506067}
}
Kostenlos starten →